The delay, narrowed approval, and extra study steps raise concerns about the status of and potential added requirements for other COVID vaccines.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
Though the continent lags well behind the rest of the world due to persistent supply inequity, it is making modest progress.
COVID-19 variants of concern (VOCs), especially the Delta (B1617.2) variant, are more virulent than the wild type, according to an Ontario-based study published in CMAJ yesterday. The cohort included 212,326 cases of non-VOCs (22.4%) and VOCs with the N501Y mutation (76.7%), such as Alpha (B117), Beta (B1351), Gamma (P1), and Delta.
Also, the persistence of depressive symptoms for more than 1 year was greater than after the Sep 11 attacks.
Though the Delta surge appears to be ebbing, several states are still experiencing overcrowded hospitals.
In other global developments, New Zealand announces a plan to loosen restrictions as Delta cases pop up in new parts of Australia.
Reinfection from SARS-CoV-2 under endemic conditions will most likely occur at a median of 16 months, according to a modeling study published late last week in The Lancet Microbe.
Two studies assessed COVID-19 vaccine hesitancy in minorities and toward specific vaccine brands.
Also, Merck says its investigational oral antiviral drug reduces the risk of COVID-19 death by 50%.
One study highlights the fallout of unstable housing on Americans' mental and physical health.
Hospitalized COVID-19 patients who were treated with remdesivir within 2 days of admission had lower mortality rates than their matched cohort, according to a study today in Clinical Infectious Diseases. The observational cohort consisted of US adults hospitalized with COVID-19 from August to November 2020; 28,855 received remdesivir and 16,887 did not.
